OnCo

Sign in to keep your watchlist

Your watched pages live in this browser. Sign in with an email link and OnCo keeps the same list on every device you use. Only your email address and your watchlist are stored.

Living with cancer·Standard of care

Anal high-grade squamous intraepithelial lesions: the decisions you may face

Cancer page →Second-opinion finder →

4 treatment settings, 3 with more than one named option. Each section lays out the options the standard of care names, what each is for, the trials behind them with their recorded results, the side effects and cautions on record, and questions to ask. Built from the cancer page's standard-of-care rows; nothing here is advice for your case.

2 options

Anal cytology or high-risk HPV testing followed by high-resolution anoscopy in people living with HIV and other high-risk groups, following the 2024 International Anal Neoplasia Society guidelines.

Guideline
NCCN Guidelines: Anal Carcinoma
The options, in plain words
HPV DNA testing and self-samplingStandard of care

A swab tested for the virus that causes cervical cancer, more accurate than the Pap smear and doable at home.

  • Higher sensitivity for precancer than cytology
  • Self-sampling reaches never-screened women
  • Long safe intervals cut cost
Circulating tumour HPV DNA (ctHPV-DNA)Established

A blood test that detects fragments of the virus DNA shed by HPV-positive throat cancers, to confirm diagnosis, track response, and catch recurrence early.

  • Highly specific to the tumour
  • Cheap, repeatable, earlier than imaging
Also referenced:HPV-positive (p16) head and neck cancer
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
HPV DNA testing and self-sampling
  • Lower specificity in young women (transient infection)
  • Needs triage (cytology, genotyping, methylation) before colposcopy
Circulating tumour HPV DNA (ctHPV-DNA)
  • Only for HPV-driven disease
  • Interventional trials proving benefit of acting on it are ongoing
Questions to ask about this decision
  1. Between HPV DNA testing and self-sampling and Circulating tumour HPV DNA (ctHPV-DNA), which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Anal Carcinoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (screening), which of the standard options do you recommend and why?
    Why: Guideline options include: Anal cytology or high-risk HPV testing followed by high-resolution anoscopy in people living with HIV and other high-risk groups, following the 2024 International Anal Neoplasia Society guidelines.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

Treatment of HSIL

2 options

Office-based ablation (electrocautery, infrared coagulation) for discrete lesions; topical fluorouracil or imiquimod for extensive or perianal disease; excision for lesions where invasion is suspected (ANCHOR).

Guideline
NCCN Guidelines: Anal Carcinoma
The options, in plain words
Thermal ablation and cryotherapy for cervical precancerStandard of care

Destroying precancerous cervical cells with a heated or frozen probe in under a minute, the tool that makes screen-and-treat possible where there are no surgeons.

  • Cheap, fast, no anaesthesia or electricity mains
  • Enables single-visit screen-and-treat
Fluorouracil (5-FU)ApprovedFluoropyrimidine antimetabolite

The 1957 chemotherapy that remains the backbone of treatment for bowel, stomach, pancreatic, anal, head and neck and breast cancers, and as a cream for skin precancers.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
Thermal ablation and cryotherapy for cervical precancer
  • No histology
  • Not suitable for large or endocervical lesions
Fluorouracil (5-FU)all recorded rates →
  • Capecitabine: take within 30 minutes after a meal. DPD deficiency (DPYD variants) causes severe toxicity: pre-treatment genotyping is recommended in Europe.
  • Capecitabine: reduce to 75% for CrCl 30-50; contraindicated below 30.
Questions to ask about this decision
  1. Between Thermal ablation and cryotherapy for cervical precancer and Fluorouracil (5-FU), which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Anal Carcinoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (treatment of hsil), which of the standard options do you recommend and why?
    Why: Guideline options include: Office-based ablation (electrocautery, infrared coagulation) for discrete lesions; topical fluorouracil or imiquimod for extensive or perianal disease; excision for lesions where invasion is suspected (ANCHOR).
  6. Am I a candidate for Fluorouracil (5-FU), and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

2 options

HPV vaccination, which protects against the HPV types that cause almost all anal cancer.

Guideline
NCCN Guidelines: Anal Carcinoma
The options, in plain words
HPV & HBV vaccinationStandard of care

Vaccines that prevent the viral infections behind cervical, throat, anal, and liver cancers. The most effective anti-cancer intervention ever created.

  • Prevents cancer outright
  • Cheap at scale
Nonavalent HPV vaccineApprovedProphylactic vaccine (virus-like particles)

A vaccine against nine HPV types that prevents about 90% of cervical cancers, and now works with a single dose.

The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
HPV & HBV vaccination
  • Coverage gaps, vaccine hesitancy
Questions to ask about this decision
  1. Between HPV & HBV vaccination and Nonavalent HPV vaccine, which do you recommend for me, and what about my case would make you choose differently?
    Why: Guidelines list several reasonable options; the choice turns on details of your tumour, your health and your priorities.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Anal Carcinoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (prevention), which of the standard options do you recommend and why?
    Why: Guideline options include: HPV vaccination, which protects against the HPV types that cause almost all anal cancer.
  6. Am I a candidate for Nonavalent HPV vaccine, and what side effects should I expect?
    Why: Knowing the expected toxicities helps you plan work, family, and supportive care.

Add these to your appointment list, or take the full question set for this cancer.

Other settings

After treatment

One path named

Repeat high-resolution anoscopy because recurrence is common; biopsy of any lesion that changes or ulcerates.

Guideline
NCCN Guidelines: Anal Carcinoma
The path, in plain words
HPV DNA testing and self-samplingStandard of care

A swab tested for the virus that causes cervical cancer, more accurate than the Pap smear and doable at home.

  • Higher sensitivity for precancer than cytology
  • Self-sampling reaches never-screened women
  • Long safe intervals cut cost
Also referenced:HPV-positive (p16) head and neck cancer
The evidence behind it

No trial record is attached to this row yet. The trials tab lists what is recruiting and the landmark trials for this cancer.

The main trade-offs on record
HPV DNA testing and self-sampling
  • Lower specificity in young women (transient infection)
  • Needs triage (cytology, genotyping, methylation) before colposcopy
Questions to ask about this decision
  1. Is HPV DNA testing and self-sampling the only reasonable path for me, or is there a trial, a different sequence or a wait-and-see option?
    Why: A single standard does not mean a single choice; timing and trials are decisions too.
  2. What is each option trying to achieve: cure, long control, or relief of symptoms, and over what time?
    Why: The aim shapes how much side effect and disruption is worth accepting.
  3. What happens if I delay, or decline this step for now? Is the decision reversible?
    Why: Some decisions can wait for a second opinion or a trial slot; others cannot. Knowing which is part of the choice.
  4. Does your recommendation follow the current guideline (NCCN Guidelines: Anal Carcinoma), and if it departs from it, why?
    Why: Departures from guidelines are sometimes right for an individual; they should be explained.
  5. For my situation (after treatment), which of the standard options do you recommend and why?
    Why: Guideline options include: Repeat high-resolution anoscopy because recurrence is common; biopsy of any lesion that changes or ulcerates.

Add these to your appointment list, or take the full question set for this cancer.

How to read this page. Options and results come from OnCo records with their sources; the settings are the standard-of-care rows on the cancer page, and the lines of therapy are on the sequencing grid. Where a setting names one path, the choice is usually about timing, trials and where to be treated: see expert centres. OnCo is orientation, not medical advice.